Jennifer A. Woyach

Apr 16, 2024 | obroncology.com | Jennifer A. Woyach |Robert A. Figlin

The development of noncovalent Bruton tyrosine kinase (BTK) inhibitors and other advances in chronic lymphocytic leukemia treatment signify that the “future is really exciting,” says Jennifer A. Woyach, MD, professor in the Division of Hematology at The Ohio State University in Columbus. Dr. Woyach speaks with Robert A.

Mar 14, 2024 | targetedonc.com | Jennifer A. Woyach

Jennifer A. Woyach, MD, a hematologist-oncologist, professor in the Division of Hematology at The Ohio State University, and co-leader of the Leukemia Research Program at The Ohio State University Comprehensive Cancer Center, discusses how pirtobrutinib (Jaypirca) compares against other Bruton tyrosine kinase (BTK) inhibitors and delves into the next steps for pirtobrutinib in the chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma space.

Feb 19, 2024 | nature.com | Adam S. Kittai |Jennifer A. Woyach

Karyotype complexity is established by enumerating the number of chromosome abnormalities present in a karyotype. In chronic lymphocytic leukemia (CLL), karyotype complexity, typically defined as ≥3 chromosome abnormalities, is an important prognostic indicator associated with poor outcomes [1]. Additionally, stratifying patients by highly complex karyotypes (≥5 chromosome abnormalities) has shown significantly poorer outcomes compared to patients with 3–4 abnormalities [2].

Jan 12, 2024 | newsbreak.com | Jennifer A. Woyach

By signing up for our newsletter, you agree to our Terms of Use and Privacy Policy

Jan 12, 2024 | targetedonc.com | Jennifer A. Woyach

Jennifer A. Woyach, MD, hematologist-oncologist, professor, the Division of Hematology, the Ohio State University Comprehensive Cancer Center– James, provides an overview on some of the updated safety and efficacy data observed with pirtobrutinib (Jaypirca) in the phase 1/2 BRUIN study (NCT03740529).